Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 16Melanoma 8Lung Neoplasms 8Neoplasm Metastasis 6Colorectal Neoplasms 6Solid Tumours 5Neoplasms 5Breast Neoplasms 4Uveal Melanoma 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Colonic Neoplasms 3Thyroid Cancer, Papillary 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Optic Nerve Glioma 1Non-small Cell Lung Cancer Metastatic 1Neurofibrosarcoma 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Paclitaxel 2trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Letrozole 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cystadenocarcinoma, Serous × AZD 6244 × Clear all
NCT00551070 2020-12-03

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡